Morgan Stanley
CADX

Morgan Stanley’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Morgan Stanley’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-102,639
Closed -$929K – 6709
2013
Q4 		$929K Buy
102,639
+54,833
+115% +$396K ﹤0.01% 3988
2013
Q3 		$301K Sell
47,806
-50,091
-51% -$318K ﹤0.01% 4659
2013
Q2 		$667K Buy
+97,897
New +$682K ﹤0.01% 4049

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley's CADX Position: Q1 2014 in Review

Morgan Stanley sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 102,639 shares — an estimated $929K sold.

Morgan Stanley first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $929K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Morgan Stanley reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Morgan Stanley sold 102,639 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $929K.
  • Morgan Stanley first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Morgan Stanley's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $929K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Morgan Stanley's 13F filing for Q1 2014, filed 13 May 2014.